Copyright Reports & Markets. All rights reserved.

Global Levodopa and Benserazide Hydrochloride Market Research Report 2022

Request for Sample of this report
Buy now

Table of Contents

    1 Levodopa and Benserazide Hydrochloride Market Overview

    • 1.1 Product Overview and Scope of Levodopa and Benserazide Hydrochloride
    • 1.2 Levodopa and Benserazide Hydrochloride Segment by Type
      • 1.2.1 Global Levodopa and Benserazide Hydrochloride Sales Growth Rate Comparison by Type (2022-2028)
      • 1.2.2 Capsules
      • 1.2.3 Tablets
      • 1.2.4 Granules
    • 1.3 Levodopa and Benserazide Hydrochloride Segment by Application
      • 1.3.1 Global Levodopa and Benserazide Hydrochloride Sales Comparison by Application: (2022-2028)
      • 1.3.2 Parkinson's Disease
      • 1.3.3 Symptomatic Parkinsonism
    • 1.4 Global Levodopa and Benserazide Hydrochloride Market Size Estimates and Forecasts
      • 1.4.1 Global Levodopa and Benserazide Hydrochloride Revenue 2017-2028
      • 1.4.2 Global Levodopa and Benserazide Hydrochloride Sales 2017-2028
      • 1.4.3 Levodopa and Benserazide Hydrochloride Market Size by Region: 2017 Versus 2021 Versus 2028

    2 Levodopa and Benserazide Hydrochloride Market Competition by Manufacturers

    • 2.1 Global Levodopa and Benserazide Hydrochloride Sales Market Share by Manufacturers (2017-2022)
    • 2.2 Global Levodopa and Benserazide Hydrochloride Revenue Market Share by Manufacturers (2017-2022)
    • 2.3 Global Levodopa and Benserazide Hydrochloride Average Price by Manufacturers (2017-2022)
    • 2.4 Manufacturers Levodopa and Benserazide Hydrochloride Manufacturing Sites, Area Served, Product Type
    • 2.5 Levodopa and Benserazide Hydrochloride Market Competitive Situation and Trends
      • 2.5.1 Levodopa and Benserazide Hydrochloride Market Concentration Rate
      • 2.5.2 The Global Top 5 and Top 10 Largest Levodopa and Benserazide Hydrochloride Players Market Share by Revenue
      • 2.5.3 Global Levodopa and Benserazide Hydrochloride Market Share by Company Type (Tier 1, Tier 2 and Tier 3)
    • 2.6 Manufacturers Mergers & Acquisitions, Expansion Plans

    3 Levodopa and Benserazide Hydrochloride Retrospective Market Scenario by Region

    • 3.1 Global Levodopa and Benserazide Hydrochloride Retrospective Market Scenario in Sales by Region: 2017-2022
    • 3.2 Global Levodopa and Benserazide Hydrochloride Retrospective Market Scenario in Revenue by Region: 2017-2022
    • 3.3 North America Levodopa and Benserazide Hydrochloride Market Facts & Figures by Country
      • 3.3.1 North America Levodopa and Benserazide Hydrochloride Sales by Country
      • 3.3.2 North America Levodopa and Benserazide Hydrochloride Revenue by Country
      • 3.3.3 United States
      • 3.3.4 Canada
    • 3.4 Europe Levodopa and Benserazide Hydrochloride Market Facts & Figures by Country
      • 3.4.1 Europe Levodopa and Benserazide Hydrochloride Sales by Country
      • 3.4.2 Europe Levodopa and Benserazide Hydrochloride Revenue by Country
      • 3.4.3 Germany
      • 3.4.4 France
      • 3.4.5 U.K.
      • 3.4.6 Italy
      • 3.4.7 Russia
    • 3.5 Asia Pacific Levodopa and Benserazide Hydrochloride Market Facts & Figures by Region
      • 3.5.1 Asia Pacific Levodopa and Benserazide Hydrochloride Sales by Region
      • 3.5.2 Asia Pacific Levodopa and Benserazide Hydrochloride Revenue by Region
      • 3.5.3 China
      • 3.5.4 Japan
      • 3.5.5 South Korea
      • 3.5.6 India
      • 3.5.7 Australia
      • 3.5.8 China Taiwan
      • 3.5.9 Indonesia
      • 3.5.10 Thailand
      • 3.5.11 Malaysia
    • 3.6 Latin America Levodopa and Benserazide Hydrochloride Market Facts & Figures by Country
      • 3.6.1 Latin America Levodopa and Benserazide Hydrochloride Sales by Country
      • 3.6.2 Latin America Levodopa and Benserazide Hydrochloride Revenue by Country
      • 3.6.3 Mexico
      • 3.6.4 Brazil
      • 3.6.5 Argentina
    • 3.7 Middle East and Africa Levodopa and Benserazide Hydrochloride Market Facts & Figures by Country
      • 3.7.1 Middle East and Africa Levodopa and Benserazide Hydrochloride Sales by Country
      • 3.7.2 Middle East and Africa Levodopa and Benserazide Hydrochloride Revenue by Country
      • 3.7.3 Turkey
      • 3.7.4 Saudi Arabia
      • 3.7.5 UAE

    4 Global Levodopa and Benserazide Hydrochloride Historic Market Analysis by Type

    • 4.1 Global Levodopa and Benserazide Hydrochloride Sales Market Share by Type (2017-2022)
    • 4.2 Global Levodopa and Benserazide Hydrochloride Revenue Market Share by Type (2017-2022)
    • 4.3 Global Levodopa and Benserazide Hydrochloride Price by Type (2017-2022)

    5 Global Levodopa and Benserazide Hydrochloride Historic Market Analysis by Application

    • 5.1 Global Levodopa and Benserazide Hydrochloride Sales Market Share by Application (2017-2022)
    • 5.2 Global Levodopa and Benserazide Hydrochloride Revenue Market Share by Application (2017-2022)
    • 5.3 Global Levodopa and Benserazide Hydrochloride Price by Application (2017-2022)

    6 Key Companies Profiled

    • 6.1 Alfresa Pharma
      • 6.1.1 Alfresa Pharma Corporation Information
      • 6.1.2 Alfresa Pharma Description and Business Overview
      • 6.1.3 Alfresa Pharma Levodopa and Benserazide Hydrochloride Sales, Revenue and Gross Margin (2017-2022)
      • 6.1.4 Alfresa Pharma Levodopa and Benserazide Hydrochloride Product Portfolio
      • 6.1.5 Alfresa Pharma Recent Developments/Updates
    • 6.2 Devatis
      • 6.2.1 Devatis Corporation Information
      • 6.2.2 Devatis Description and Business Overview
      • 6.2.3 Devatis Levodopa and Benserazide Hydrochloride Sales, Revenue and Gross Margin (2017-2022)
      • 6.2.4 Devatis Levodopa and Benserazide Hydrochloride Product Portfolio
      • 6.2.5 Devatis Recent Developments/Updates
    • 6.3 Kyowa Kirin
      • 6.3.1 Kyowa Kirin Corporation Information
      • 6.3.2 Kyowa Kirin Description and Business Overview
      • 6.3.3 Kyowa Kirin Levodopa and Benserazide Hydrochloride Sales, Revenue and Gross Margin (2017-2022)
      • 6.3.4 Kyowa Kirin Levodopa and Benserazide Hydrochloride Product Portfolio
      • 6.3.5 Kyowa Kirin Recent Developments/Updates
    • 6.4 Neuraxpharm Arzneimittel
      • 6.4.1 Neuraxpharm Arzneimittel Corporation Information
      • 6.4.2 Neuraxpharm Arzneimittel Description and Business Overview
      • 6.4.3 Neuraxpharm Arzneimittel Levodopa and Benserazide Hydrochloride Sales, Revenue and Gross Margin (2017-2022)
      • 6.4.4 Neuraxpharm Arzneimittel Levodopa and Benserazide Hydrochloride Product Portfolio
      • 6.4.5 Neuraxpharm Arzneimittel Recent Developments/Updates
    • 6.5 Roche Pharma
      • 6.5.1 Roche Pharma Corporation Information
      • 6.5.2 Roche Pharma Description and Business Overview
      • 6.5.3 Roche Pharma Levodopa and Benserazide Hydrochloride Sales, Revenue and Gross Margin (2017-2022)
      • 6.5.4 Roche Pharma Levodopa and Benserazide Hydrochloride Product Portfolio
      • 6.5.5 Roche Pharma Recent Developments/Updates
    • 6.6 Taiyo Holdings
      • 6.6.1 Taiyo Holdings Corporation Information
      • 6.6.2 Taiyo Holdings Description and Business Overview
      • 6.6.3 Taiyo Holdings Levodopa and Benserazide Hydrochloride Sales, Revenue and Gross Margin (2017-2022)
      • 6.6.4 Taiyo Holdings Levodopa and Benserazide Hydrochloride Product Portfolio
      • 6.6.5 Taiyo Holdings Recent Developments/Updates
    • 6.7 Teva Pharmaceutical Industries
      • 6.6.1 Teva Pharmaceutical Industries Corporation Information
      • 6.6.2 Teva Pharmaceutical Industries Description and Business Overview
      • 6.6.3 Teva Pharmaceutical Industries Levodopa and Benserazide Hydrochloride Sales, Revenue and Gross Margin (2017-2022)
      • 6.4.4 Teva Pharmaceutical Industries Levodopa and Benserazide Hydrochloride Product Portfolio
      • 6.7.5 Teva Pharmaceutical Industries Recent Developments/Updates
    • 6.8 Aida Pharmaceutical
      • 6.8.1 Aida Pharmaceutical Corporation Information
      • 6.8.2 Aida Pharmaceutical Description and Business Overview
      • 6.8.3 Aida Pharmaceutical Levodopa and Benserazide Hydrochloride Sales, Revenue and Gross Margin (2017-2022)
      • 6.8.4 Aida Pharmaceutical Levodopa and Benserazide Hydrochloride Product Portfolio
      • 6.8.5 Aida Pharmaceutical Recent Developments/Updates
    • 6.9 Baiyunshan Pharmaceutical
      • 6.9.1 Baiyunshan Pharmaceutical Corporation Information
      • 6.9.2 Baiyunshan Pharmaceutical Description and Business Overview
      • 6.9.3 Baiyunshan Pharmaceutical Levodopa and Benserazide Hydrochloride Sales, Revenue and Gross Margin (2017-2022)
      • 6.9.4 Baiyunshan Pharmaceutical Levodopa and Benserazide Hydrochloride Product Portfolio
      • 6.9.5 Baiyunshan Pharmaceutical Recent Developments/Updates
    • 6.10 Fuda Pharmaceutical
      • 6.10.1 Fuda Pharmaceutical Corporation Information
      • 6.10.2 Fuda Pharmaceutical Description and Business Overview
      • 6.10.3 Fuda Pharmaceutical Levodopa and Benserazide Hydrochloride Sales, Revenue and Gross Margin (2017-2022)
      • 6.10.4 Fuda Pharmaceutical Levodopa and Benserazide Hydrochloride Product Portfolio
      • 6.10.5 Fuda Pharmaceutical Recent Developments/Updates
    • 6.11 Xinhua Pharmaceutical
      • 6.11.1 Xinhua Pharmaceutical Corporation Information
      • 6.11.2 Xinhua Pharmaceutical Levodopa and Benserazide Hydrochloride Description and Business Overview
      • 6.11.3 Xinhua Pharmaceutical Levodopa and Benserazide Hydrochloride Sales, Revenue and Gross Margin (2017-2022)
      • 6.11.4 Xinhua Pharmaceutical Levodopa and Benserazide Hydrochloride Product Portfolio
      • 6.11.5 Xinhua Pharmaceutical Recent Developments/Updates
    • 6.12 Yishengyuan Pharmaceutical
      • 6.12.1 Yishengyuan Pharmaceutical Corporation Information
      • 6.12.2 Yishengyuan Pharmaceutical Levodopa and Benserazide Hydrochloride Description and Business Overview
      • 6.12.3 Yishengyuan Pharmaceutical Levodopa and Benserazide Hydrochloride Sales, Revenue and Gross Margin (2017-2022)
      • 6.12.4 Yishengyuan Pharmaceutical Levodopa and Benserazide Hydrochloride Product Portfolio
      • 6.12.5 Yishengyuan Pharmaceutical Recent Developments/Updates

    7 Levodopa and Benserazide Hydrochloride Manufacturing Cost Analysis

    • 7.1 Levodopa and Benserazide Hydrochloride Key Raw Materials Analysis
      • 7.1.1 Key Raw Materials
      • 7.1.2 Key Suppliers of Raw Materials
    • 7.2 Proportion of Manufacturing Cost Structure
    • 7.3 Manufacturing Process Analysis of Levodopa and Benserazide Hydrochloride
    • 7.4 Levodopa and Benserazide Hydrochloride Industrial Chain Analysis

    8 Marketing Channel, Distributors and Customers

    • 8.1 Marketing Channel
    • 8.2 Levodopa and Benserazide Hydrochloride Distributors List
    • 8.3 Levodopa and Benserazide Hydrochloride Customers

    9 Levodopa and Benserazide Hydrochloride Market Dynamics

    • 9.1 Levodopa and Benserazide Hydrochloride Industry Trends
    • 9.2 Levodopa and Benserazide Hydrochloride Market Drivers
    • 9.3 Levodopa and Benserazide Hydrochloride Market Challenges
    • 9.4 Levodopa and Benserazide Hydrochloride Market Restraints

    10 Global Market Forecast

    • 10.1 Levodopa and Benserazide Hydrochloride Market Estimates and Projections by Type
      • 10.1.1 Global Forecasted Sales of Levodopa and Benserazide Hydrochloride by Type (2023-2028)
      • 10.1.2 Global Forecasted Revenue of Levodopa and Benserazide Hydrochloride by Type (2023-2028)
    • 10.2 Levodopa and Benserazide Hydrochloride Market Estimates and Projections by Application
      • 10.2.1 Global Forecasted Sales of Levodopa and Benserazide Hydrochloride by Application (2023-2028)
      • 10.2.2 Global Forecasted Revenue of Levodopa and Benserazide Hydrochloride by Application (2023-2028)
    • 10.3 Levodopa and Benserazide Hydrochloride Market Estimates and Projections by Region
      • 10.3.1 Global Forecasted Sales of Levodopa and Benserazide Hydrochloride by Region (2023-2028)
      • 10.3.2 Global Forecasted Revenue of Levodopa and Benserazide Hydrochloride by Region (2023-2028)

    11 Research Finding and Conclusion

      12 Methodology and Data Source

      • 12.1 Methodology/Research Approach
        • 12.1.1 Research Programs/Design
        • 12.1.2 Market Size Estimation
        • 12.1.3 Market Breakdown and Data Triangulation
      • 12.2 Data Source
        • 12.2.1 Secondary Sources
        • 12.2.2 Primary Sources
      • 12.3 Author List

      Summary:

      Industry Insights
      Due to the COVID-19 pandemic, the global Levodopa and Benserazide Hydrochloride market size is estimated to be worth US$ million in 2021 and is forecast to a readjusted size of US$ million by 2028 with a CAGR of % during the forecast period 2022-2028. Fully considering the economic change by this health crisis, the Europe Levodopa and Benserazide Hydrochloride market is estimated at US$ million in 2022, while the United States and China are forecast to reach US$ million and US$ million by 2028, respectively. The proportion of the United States is % in 2022, while Chinese percentage is %, and it is predicted that China market share will reach % in 2028, trailing a CAGR of % through the analysis period. As for the Europe Levodopa and Benserazide Hydrochloride landscape, Germany is projected to reach US$ million by 2028. and in Asia, the notable markets are Japan and South Korea, CAGR is % and % respectively for the next 6-year period.
      Capsules accounting for % of the Levodopa and Benserazide Hydrochloride global market in 2021, is projected to value US$ million by 2028, growing at a revised % CAGR from 2022 to 2028. While Parkinson's Disease segment is altered to an % CAGR throughout this forecast period and will hold a share about % in 2028.
      The global major manufacturers of Levodopa and Benserazide Hydrochloride include Alfresa Pharma, Devatis, Kyowa Kirin, Neuraxpharm Arzneimittel, Roche Pharma, Taiyo Holdings, Teva Pharmaceutical Industries, Aida Pharmaceutical and Baiyunshan Pharmaceutical, etc. In terms of revenue, the global 3 largest players have a % market share of Levodopa and Benserazide Hydrochloride in 2021.
      This report focuses on Levodopa and Benserazide Hydrochloride volume and value at the global level, regional level, and company level. From a global perspective, this report represents overall Levodopa and Benserazide Hydrochloride market size by analysing historical data and future prospect. Regionally, this report focuses on several key regions: North America, Europe, China and Japan, etc.
      Key Drivers & Barriers
      High-impact rendering factors and drivers have been studied in this report to aid the readers to understand the general development. Moreover, the report includes restraints and challenges that may act as stumbling blocks on the way of the players. This will assist the users to be attentive and make informed decisions related to business. Specialists have also laid their focus on the upcoming business prospects.
      Post-covid-19 Outlook
      The readers in the section will understand how the Levodopa and Benserazide Hydrochloride market scenario changed across the globe during the pandemic and post-pandemic. The study is done keeping in view the changes in aspects such as sales, demand and supply chain. The industry experts have also highlighted the key factors that will help create opportunities for players and stabilize the overall industry in the years to come.
      Segmental Outlook
      Key segments including type and application have been elaborated in this report. The consultants at QY Research have studied every segment and provided the market size using historical data. They have also talked about the growth opportunities that the segment may pose in the future. This study bestows sales and revenue data by type, and application during the historical period (2017-2022) and forecast period (2023-2028).
      Segment by Type
      Capsules
      Tablets
      Granules
      Segment by Application
      Parkinson's Disease
      Symptomatic Parkinsonism
      Regional Outlook
      This section of the report provides key insights regarding various regions and the key players operating in each region. Economic, social, environmental, technological, and political factors have been taken into consideration while assessing the growth of the particular region/country. The readers will also get their hands on the revenue and sales data of each region and country for the period 2017-2028. This information derived through comprehensive research will help the reader to get familiar with the potential value of the investment in a particular region.
      North America
      United States
      Canada
      Europe
      Germany
      France
      U.K.
      Italy
      Russia
      Asia-Pacific
      China
      Japan
      South Korea
      India
      Australia
      China Taiwan
      Indonesia
      Thailand
      Malaysia
      Latin America
      Mexico
      Brazil
      Argentina
      Middle East & Africa
      Turkey
      Saudi Arabia
      UAE
      Competitive Scenario
      In this section, the readers will gain an understanding of the key players competing. The experts at QY Research have studied the key growth strategies, such as innovative trends and developments, intensification of product portfolio, mergers and acquisitions, collaborations, new product innovation, and geographical expansion, undertaken by these participants to maintain their presence. Apart from business strategies, the study includes current developments and key financials. The readers will also get access to the data related to global revenue, price, and sales by manufacturers for the period 2017-2022. This all-inclusive report will certainly serve the clients to stay updated and make effective decisions in their businesses. Some of the prominent players reviewed in the research report include:
      Alfresa Pharma
      Devatis
      Kyowa Kirin
      Neuraxpharm Arzneimittel
      Roche Pharma
      Taiyo Holdings
      Teva Pharmaceutical Industries
      Aida Pharmaceutical
      Baiyunshan Pharmaceutical
      Fuda Pharmaceutical
      Xinhua Pharmaceutical
      Yishengyuan Pharmaceutical
      Frequently Asked Questions
      Which product segment grabbed the largest share in the Levodopa and Benserazide Hydrochloride market?
      How is the competitive scenario of the Levodopa and Benserazide Hydrochloride market?
      Which are the key factors aiding the Levodopa and Benserazide Hydrochloride market growth?
      Which are the prominent players in the Levodopa and Benserazide Hydrochloride market?
      Which region holds the maximum share in the Levodopa and Benserazide Hydrochloride market?
      What will be the CAGR of the Levodopa and Benserazide Hydrochloride market during the forecast period?
      Which application segment emerged as the leading segment in the Levodopa and Benserazide Hydrochloride market?
      What key trends are likely to emerge in the Levodopa and Benserazide Hydrochloride market in the coming years?
      What will be the Levodopa and Benserazide Hydrochloride market size by 2028?
      Which company held the largest share in the Levodopa and Benserazide Hydrochloride market?
      Buy now